Anacor Pharmaceuticals Inc.
This article was originally published in Start Up
Anacor Pharmaceuticals Inc. is developing a new class of antibiotics against a novel target discovered by its scientific founders. The company aims to create drugs that will address the growing problem of bacterial resistance to existing antibiotics, and also for use against biowarfare pathogens, such as anthrax, likely to be deployed in a bioterror attack.
You may also be interested in...
Six years ago, David Perry was one of the rock stars of the Web, the founding CEO of Chemdex-Ventro. He stuck with it as the company unraveled, shutting down most of the businesses he'd built, and merging the remainder into what is now an OTC-traded software company. Now he's applying the lessons he learned to his current company, Anacor Pharmaceuticals, a start-up which has discovered a small handful of now clinical-stage compounds.
In Vivo's editors pick January's most significant deals, including Roche's acquisition of Flatiron and Moderna's latest big private fundraising. (Free article.)